CD34 and systemic sclerosis: With regard to the selection of cells for the graft, a recent multicenter retrospective study has demonstrated that the use of selected CD34+ cells for AHSCT in patients with SSc did not add any benefit to the outcome with respect to the use of un-manipulated cells (36).